Management of interstitial lung disease associated with connective tissue disease

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Mathai, Stephen C ^a   Danoff, Sonye K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL PRODUCT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMATINIB; METHOTREXATE; MYCOPHENOLATE MOFETIL; PIRFENIDONE; POMALIDOMIDE; RITUXIMAB; RESPIRATORY TRACT AGENT;

CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; COUGHING; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG DISEASE; LUNG TRANSPLANTATION; MANAGED CARE; MIXED CONNECTIVE TISSUE DISEASE; PALLIATIVE THERAPY; PATIENT ASSESSMENT; POLYMYOSITIS; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCLERODERMA; SHRINKING LUNG SYNDROME; SJOEGREN SYNDROME; SLEEP DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT PLANNING; AUTOIMMUNE DISEASES; COMPLICATION; CONNECTIVE TISSUE DISEASES; LUNG DISEASES, INTERSTITIAL;

AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RESPIRATORY SYSTEM AGENTS; RISK FACTORS;

EID: 84960172152     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h6819     Document Type: Review

References (151)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
3. Sacks JJ, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005. Arthritis Care Res (Hoboken) 2010;62:460-4.
4. Yunt ZX, Solomon JJ. Lung disease in rheumatoid arthritis. Rheum Dis Clin North Am 2015;41:225-36.
5. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001;56:622-7.
6. McDonagh J, Greaves M, Wright AR, et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol 1994;33:118-22.
7. Cortet B, Perez T, Roux N, et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997;56:596-600.
8. Cervantes-Perez P, Toro-Perez AH, Rodriguez-Jurado P. Pulmonary involvement in rheumatoid arthritis. JAMA 1980;243:1715-9.
9. Lamblin C, Bergoin C, Saelens T, et al. Interstitial lung diseases in collagen vascular diseases. Eur Respir J Suppl 2001;32:69s-80s.
10. Young A, Koduri G, Batley M, et al; Early Rheumatoid Arthritis Study Group. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007;46:350-7.
11. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011;183:372-8.
12. Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994;21:33-6.
13. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fiftyeight matched controls. Am J Med 1969;46:428-40.
14. Mathai SC, Hummers LK. Pulmonary hypertension associated with connective tissue disease. In: Dellaripa PF, Fischer A, Flaherty KR, eds. Pulmonary manifestations of rheumatic diseases: A comprehensive guide. 1st ed. Springer, 2014:139-66.
15. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
16. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue diseaseassociated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7.
17. Khanna D, Gladue H, Channick R, et al; Scleroderma Foundation and Pulmonary Hypertension Association. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 2013;65:3194-201.
18. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis Rheum 2009;60:569-77.
19. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 2007;66:754-63.
20. Zhang XJ, Bonner A, Hudson M; Canadian Scleroderma Research Group. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. J Rheumatol 2013;40:850-8.
21. Wells AU, Margaritopoulos GA, Antoniou KM, et al. Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med 2014;35:213-21.
22. Briggs DC, Vaughan RW, Welsh KI, et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338:661-2.
23. Hu PQ, Fertig N, Medsger TA Jr, et al. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003;48:1363-73.
24. Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: A systematic review. Chest 2014;146:422-36.
25. Mittoo S, Fell CD. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care 2014;35:249-54.
26. Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004;63:297-301.
27. Chua F, Higton AM, Colebatch AN, et al. Idiopathic inflammatory myositis-associated interstitial lung disease: Ethnicity differences and lung function trends in a British cohort. Rheumatology (Oxford) 2012;51:1870-6.
28. Eisenberg H, Dubois EL, Sherwin RP, et al. Diffuse interstitial lung disease in systemic lupus erythematosus. Ann Intern Med 1973;79:37-45.
29. Ter Borg EJ, Groen H, Horst G, et al. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum 1990;20:164-73.
30. Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum 1989;32:1226-32.
31. Matthay RA, Schwarz MI, Petty TL, et al. Pulmonary manifestations of systemic lupus erythematosus: Review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975;54:397-409.
32. Bertoli AM, Fernandez M, Alarcon GS, et al. Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): Factors predictive of self-reported work disability. Ann Rheum Dis 2007;66:12-7.
33. Rolla G, Brussino L, Bertero MT, et al. Respiratory function in systemic lupus erythematosus: Relation with activity and severity. Lupus 1996;5:38-43.
34. Carmier D, Diot E, Diot P. Shrinking lung syndrome: Recognition, pathophysiology and therapeutic strategy. Expert Rev Respir Med 2011;5:33-9.
35. Lee CS, Chen TL, Tzen CY, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 2002;21:391-6.
36. Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009;28:639-46.
37. Hayashi S, Tanaka M, Kobayashi H, et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 2008;35:260-9.
38. Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis: Analysis of 192 Chinese cases. Clin Rheumatol 2011;30:1595-601.
39. Ji SY, Zeng FQ, Guo Q, et al. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: A retrospective study. Chin Med J (Engl) 2010;123:517-22.
40. Fujisawa T, Hozumi H, Kono M, et al. Prognostic factors for myositisassociated interstitial lung disease. PLoS One 2014;9:e98824.
41. Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: A retrospective cohort study. Clin Rheumatol 2007;26:1647-54.
42. Won Huh J, Soon Kim D, Keun Lee C, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007;101:1761-9.
43. Palm O, Garen T, Enger TB, et al. Clinical pulmonary involvement in primary Sjogren's syndrome: Prevalence, quality of life and mortality-a retrospective study based on registry data. Rheumatology 2013;52:173-9.
44. Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjogren syndrome in Spain-clinical and immunologic expression in 1010 patients. Medicine 2008;87:210-9.
45. Yazisiz V, Arslan G, Ozbudak IH, et al. Lung involvement in patients with primary Sjogren's syndrome: What are the predictors? Rheumatol Int 2010;30:1317-24.
46. Uffmann M, Kiener HP, Bankier AA, et al. Lung manifestation in asymptomatic patients with primary Sjogren syndrome: Assessment with high resolution CT and pulmonary function tests. J Thorac Imag 2001;16:282-9.
47. Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjogren's syndrome. Clin Chest Med 1998;19:687-99.
48. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjogren syndrome. Chest 2006;130:1489-95.
49. Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjogren's syndrome. Am J Respir Crit Care 2005;171:632-8.
50. Boitiaux JF, Debray MP, Nicaise-Roland P, et al. Idiopathic interstitial lung disease with anti-SSA antibody. Rheumatology 2011;50:2245-50.
51. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59.
52. Tani C, Carli L, Vagnani S, et al. The diagnosis and classification of mixed connective tissue disease. J Autoimmun 2014;48-49:46-9.
53. Szodoray P, Hajas A, Kardos L, et al. Distinct phenotypes in mixed connective tissue disease: Subgroups and survival. Lupus 2012;21:1412-22.
54. Gunnarsson R, Aalokken TM, Molberg O, et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: A nationwide, cross-sectional study. Ann Rheum Dis 2012;71:1966-72.
55. Gunnarsson R, El-Hage F, Aalokken TM, et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 2016;55:103-8.
56. Luo Q, Xie J, Han Q, et al. Prevalence of venous thromboembolic events and diagnostic performance of the wells score and revised geneva scores for pulmonary embolism in patients with interstitial lung disease: A prospective study. Heart Lung Circ 2014;23:778-85.
57. Ungprasert P, Srivali N, Kittanamongkolchai W. Systemic sclerosis and risk of venous thromboembolism: A systematic review and meta-analysis. Mod Rheumatol 2015; published online 28 May.
58. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3-19.
59. Bohan A, Peter JB. Polymyositis and dermatomyositis.1. N Engl J Med 1975;292:344-7.
60. Bohan A, Peter JB. Polymyositis and dermatomyositis. 2. N Engl J Med 1975;292:403-7.
61. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur Respir J 2015;46:976-87.
62. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005;52:1571-6.
63. Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: Expanding the clinical spectrum. Arthritis Care Res 2013;65:1307-15.
64. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
65. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med 2008;177:1248-54.
66. Johannson K, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: A proposal. Curr Respir Care Rep 2013; 2.
67. Ghatol A, Ruhl AP, Danoff SK. Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: A case series and comprehensive review of the literature. Lung 2012;190:373-80.
68. Judge EP, Fabre A, Adamali HI, et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012;40:93-100.
69. Johannson KA, Vittinghoff E, Lee K, et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J 2014;43:1124-31.
70. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest 2010;137:1164-71.
71. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: An analysis of data from three randomised controlled trials. Lancet Respir Med 2013;1:369-76.
72. Hoshi K, Matsuda M, Ishikawa M, et al. Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clin Rheumatol 2004;23:252-5.
73. Park IN, Kim DS, Shin TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007;132:214-20.
74. Tachikawa R, Tomii K, Ueda H, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: Collagen vascular diseases-related versus idiopathic. Respiration 2012;83:20-7.
75. Parambil JG, Myers JL, Ryu JH. Diffuse alveolar damage-uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest 2006;130:553-8.
76. Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009;187:201-6.
77. Diot E, Carmier D, Marquette D, et al. IV Immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest 2011;140:562-3.
78. Tashkin DP, Elashoff R, Clements PJ, et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
79. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
80. Ando K, Motojima S, Doi T, et al. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with sclerodermarelated interstitial lung disease. Respir Invest 2013;51:69-75.
81. Iudici M, Van Der Goes MC, Valentini G, et al. Glucocorticoids in systemic sclerosis: Weighing the benefits and risks-a systematic review. Clin Exp Rheumatol 2013;31:157-65.
82. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
83. Gordon PA, Winer JB, Hoogendijk JE, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012;8:CD003643.
84. Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in the past 35 years? Chest 2010;138:1464-74.
85. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol 2012;24:635-41.
86. Paone C, Chiarolanza I, Cuomo G, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007;25:613-6.
87. Berezne A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study. J Rheumatol 2008;35:1064-72.
88. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
89. Domiciano DS, Bonfa E, Borges CT, et al. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol 2011;30:223-9.
90. Broad K, Pope JE. The efficacy of treatment for systemic sclerosis interstitial lung disease: Results from a meta-analysis. Med Sci Monit 2010;16:RA187-90.
91. Wanchu A, Suryanaryana BS, Sharma S, et al. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: A prospective open study. Int J Rheum Dis 2009;12:239-42.
92. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
93. Wells AU, Latsi P, McCune WJ. Daily cyclophosphamide for scleroderma: Are patients with the most to gain underrepresented in this trial? Am J Respir Crit Care Med 2007;176:952-3.
94. Tashkin DP, Elashoff R, Clements PJ; Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34.
95. Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72:482-92.
96. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review. Semin Arthritis Rheum 2014;43:613-26.
97. Carson CW, Cannon GW, Egger MJ, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987;16:186-95.
98. Sathi N, Chikura B, Kaushik VV, Wiswell R, et al. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol 2012;31:79-83.
99. Walker KM, Pope J; Scleroderma Clinical Trials Consortium, Canadian Scleroderma Research Group. Treatment of systemic sclerosis complications: What to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012;42:42-55.
100. Coppo P, Clauvel JP, Bengoufa D, et al. Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: A subset of myositis associated with a favourable outcome. Rheumatology (Oxford) 2002;41:1040-6.
101. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013;40: 640-6.
102. Tzouvelekis A, Galanopoulos N, Bouros E, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosisassociated interstitial lung disease: A meta-analysis. Pulm Med 2012;2012:143637.
103. Yilmaz N, Can M, Kocakaya D, et al. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: A case series. Int J Rheum Dis 2014;17:923-8.
104. Panopoulos ST, Bournia VK, Trakada G, et al. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: A 2-year case control study. Lung 2013;191:483-9.
105. Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 2013;107:890-6.
106. Boddana P, Webb LH, Unsworth J, et al. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: An emerging clinical phenomenon? Clin Transplant 2011;25:417-9.
107. Fassbinder T, Saunders U, Mickholz E, et al. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res Ther 2015;17:92.
108. Kurita T, Yasuda S, Amengual O, et al. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus 2015;24:3-9.
109. Gordon P, Gooptu B. Tacrolimus in idiopathic inflammatory myopathyassociated interstitial lung disease: Defining roles and responders. Rheumatology (Oxford) 2015;54:3-4.
110. Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 2013;107:745-52.
111. Labirua-Iturburu A, Selva-O'Callaghan A, Martinez-Gomez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetaseassociated interstitial lung disease. Clin Exp Rheumatol 2013;31:436-9.
112. Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012;30:S17-22.
113. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
114. Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: Rituximab as rescue therapy. Eur Respir J 2012;40:641-8.
115. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19:353-9.
116. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011;70:1003-9.
117. Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, openlabel pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011;63:3540-6.
118. Horai Y, Miyamura T, Shimada K, et al. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther 2012;37:117-21.
119. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: Analysis of 122 cases. Semin Arthritis Rheum 2011;41:256-64.
120. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-41.
121. Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006;54:184-91.
122. Launay D, Humbert M, Berezne A, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011;140:1016-24.
123. Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011;63:2456-64.
124. Volkmann ER, Saggar R, Khanna D, et al. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol 2014;66:1900-8.
125. Pihtili A, Bingol Z, Kiyan E, et al. Obstructive sleep apnea is common in patients with interstitial lung disease. Sleep Breath 2013;17:1281-8.
126. Prado GF, Allen RP, Trevisani VM, et al. Sleep disruption in systemic sclerosis (scleroderma) patients: Clinical and polysomnographic findings. Sleep Med 2002;3:341-5.
127. Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009;136:772-8.
128. Mermigkis C, Chapman J, Golish J, et al. Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis. Lung 2007;185:173-8.
129. Won CH, Kryger M. Sleep in patients with restrictive lung disease. Clin Chest Med 2014;35:505-12.
130. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: A randomised controlled trial. Lancet 2000;355:362-8.
131. Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: A qualitative study of patients, informal caregivers and health professionals. Palliat Med 2013;27:869-76.
132. Bajwah S, Ross JR, Peacock JL, et al. Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: A systematic review of the literature. Thorax 2013;68:867-79.
133. Hershcovici T, Jha LK, Johnson T, et al. Systematic review: The relationship between interstitial lung diseases and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011;34:1295-305.
134. Kilduff CE, Counter MJ, Thomas GA, et al. Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: An intervention study. Cough 2014;10:4.
135. Tanner K, Roy N, Merrill RM, et al. Comparing nebulized water versus saline after laryngeal desiccation challenge in Sjogren's syndrome. Laryngoscope 2013;123:2787-92.
136. Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: A randomized trial. Ann Intern Med 2012;157:398-406.
137. Bennett CL, Schumock GT, Desai AA, et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 2002;113:603-6.
138. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-42.
139. Higginson IJ, Bausewein C, Reilly CC, et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: A randomised controlled trial. Lancet Respir Med 2014;2:979-87.
140. Van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial. JAMA 2014;311:2490-8.
141. Christie JD, Edwards LB, Kucheryavaya AY, et al; International Society of Heart and Lung Transplantation. The registry of the international society for heart and lung transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012;31:1073-86.
142. Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006;54:3954-61.
143. Saggar R, Khanna D, Furst DE, et al. Systemic sclerosis and bilateral lung transplantation: A single centre experience. Eur Respir J 2010;36:893-900.
144. Shitrit D, Amital A, Peled N, et al. Lung transplantation in patients with scleroderma: Case series, review of the literature, and criteria for transplantation. Clin Transplant 2009;23:178-83.
145. Sottile PD, Iturbe D, Katsumoto TR, et al. Outcomes in systemic sclerosisrelated lung disease after lung transplantation. Transplantation 2013;95:975-80.
146. Bernstein EJ, Peterson ER, Sell JL, et al. Survival of adults with systemic sclerosis following lung transplantation: A nationwide cohort study. Arthritis Rheumatol 2015;67:1314-22.
147. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An updated of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3-19.
148. Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(25 suppl):D60-72.
149. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 2014;146:449-75.
150. Miura Y, Saito T, Fujita K, et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:235-8.
151. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013;5:205ra136.